Tendências da execução de mastectomia no câncer de mama inicial em uma instituição pública com acesso limitado: uma coorte retrospectiva
DOI:
https://doi.org/10.29289/2594539420250004Palavras-chave:
breast neoplasms, mastectomy, subcutaneous, segmental, mammaplastyResumo
Objective: To assess trends in breast surgery, Breast-conserving surgery (BCS) and mastectomy, in an institution with limited access to health resources. Methods: A retrospective cohort study was carried out in patients who underwent surgery for non-metastatic breast cancer between 2012 and 2019 at the Hospital Geral de Fortaleza (HGF), an institution that exclusively treats patients from the Brazilian public health system (SUS). The main objective of the study was to evaluate the rates of mastectomy in the period, with or without immediate reconstruction, as well as BCS rates. The χ2 test, with Bonferroni adjustment, was applied to the relative frequency of the procedures performed to test for statistical significance in the evolution of the frequencies of surgeries over the years. Results: A total of 805 patients underwent surgical treatment for non-metastatic breast cancer, with an average of 100 surgeries per year (range 85–118) during the study period. Mastectomy was performed in 552 cases (68.57%), while 253 patients underwent BCS (31.42%). Among the patients who underwent mastectomy, 181 (32.78%) had immediate reconstruction, with the highest proportion using implants (92.26%). No statistical difference was observed between mastectomies with or without reconstruction throughout the period (p=0.6635), with a statistically significant difference between BCS (p=0.04281) and mastectomies. Conclusion: There was no increase in the rates of mastectomies, with and without immediate reconstruction, over the years, but a trend towards an increase in BCS. Further studies are needed to better understand this trend in settings with limited access to health care.
Downloads
Referências
1. Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023;73(1):17-48. https://doi.org/10.3322/caac.21763
2. Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229-63. https://doi.org/10.3322/caac.21834
3. Santos M de O, Lima FC da S de, Martins LFL, Oliveira JFP, Almeida LM de, Cancela M de C. Estimativa de incidência de câncer no Brasil, 2023-2025. Rev Bras Cancerol. 2023;69(1):e-213700. https://doi.org/10.32635/2176-9745.RBC.2023v69n1.3700
4. Balic M, Thomssen C, Gnant M, Harbeck N. St. Gallen/Vienna 2023: Optimization of treatment for patients with primary breast cancer - a brief summary of the consensus discussion. Breast Care. 2023;18(3):213-22. https://doi.org/10.1159/000530584
5. Gradishar WJ, Moran MS, Abraham J, Abramson V, Aft R, Agnese D, et al. NCCN Guidelines® Insights: Breast Cancer, Version 4.2023. J Natl Compr Canc Netw. 2023;21(6):594-608. https://doi.org/10.6004/jnccn.2023.0031
6. Halsted WS. I. The results of radical operations for the cure of carcinoma of the breast. Ann Surg. 1907;46(1):1-19. https://doi.org/10.1097/00000658-190707000-00001
7. Fisher B, Anderson S. Conservative surgery for the management of invasive and noninvasive carcinoma of the breast: NSABP trials. National Surgical Adjuvant Breast and Bowel Project. World J Surg. 1994;18(1):63-9. https://doi.org/10.1007/BF00348193
8. Veronesi U, Zucali R, Luini A. Local control and survival in early breast cancer: the Milan trial. Int J Radiat Oncol Biol Phys. 1986;12(5):717-20. https://doi.org/10.1016/0360-3016(86)90027-1
9. Neuburger J, Macneill F, Jeevan R, van der Meulen JH, Cromwell DA. Trends in the use of bilateral mastectomy in England from 2002 to 2011: retrospective analysis of hospital episode statistics. BMJ Open. 2013;3(8):e003179. https://doi.org/10.1136/bmjopen-2013-003179
10. Metcalfe K, Gershman S, Ghadirian P, Lynch HT, Snyder C, Tung N, et al. Contralateral mastectomy and survival after breast cancer in carriers of BRCA1 and BRCA2 mutations: retrospective analysis. BMJ. 2014;348:g226. https://doi.org/10.1136/bmj.g226
11. Albornoz CR, Matros E, Lee CN, Hudis CA, Pusic AL, Elkin E, et al. Bilateral mastectomy versus breast-conserving surgery for early-stage breast cancer: the role of breast reconstruction. Plast Reconstr Surg. 2015;135(6):1518-26. https://doi.org/10.1097/PRS.0000000000001276
12. Tuttle TM, Habermann EB, Grund EH, Morris TJ, Virnig BA. Increasing use of contralateral prophylactic mastectomy for breast cancer patients: a trend toward more aggressive surgical treatment. J Clin Oncol. 2007;25(33):5203-9. https://doi.org/10.1200/JCO.2007.12.3141
13. Habermann EB, Abbott A, Parsons HM, Virnig BA, Al-Refaie WB, Tuttle TM. Are mastectomy rates really increasing in the United States? J Clin Oncol. 2010;28(21):3437-41. https://doi.org/10.1200/JCO.2009.27.6774
14. Kummerow KL, Du L, Penson DF, Shyr Y, Hooks MA. Nationwide trends in mastectomy for early-stage breast cancer. JAMA Surg. 2015;150(1):9-16. https://doi.org/10.1001/jamasurg.2014.2895
15. Ahern TP, Larsson H, Garne JP, Cronin-Fenton DP, Sørensen HT, Lash TL. Trends in breast-conserving surgery in Denmark, 1982-2002. Eur J Epidemiol. 2008;23(2):109-14. https://doi.org/10.1007/s10654-007-9207-1
16. Gomez SL, Lichtensztajn D, Kurian AW, Telli ML, Chang ET, Keegan TH, et al. Increasing mastectomy rates for early-stage breast cancer? Population-based trends from California. J Clin Oncol. 2010;28(10):e155-7; author reply e158. https://doi.org/10.1200/JCO.2009.26.1032
17. Brasil. Legislação Informatizada - Lei nº 12.802, de 24 de abril de 2013 - Publicação Original [Internet]. Brasil; 2013 [accessed July 29, 2023]. Available at: https://www2.camara.leg.br/legin/fed/lei/2013/lei-12802-24-abril-2013-775848-publicacaooriginal-139619-pl.html
18. Freitas-Júnior R, Gagliato DM, Moura Filho JWC, Gouveia PA, Rahal RMS, Paulinelli RR, et al. Trends in breast cancer surgery at Brazil's public health system. J Surg Oncol. 2017;115(5):544-9. https://doi.org/10.1002/jso.24572
19. Fancellu A, Sanna V, Cottu P, Feo CF, Scanu AM, Farina G, et al. Mastectomy patterns, but not rates, are changing in the treatment of early breast cancer. Experience of a single European institution on 2315 consecutive patients. Breast. 2018;39:1-7. https://doi.org/10.1016/j.breast.2018.02.003
20. Retrouvey H, Solaja O, Gagliardi AR, Webster F, Zhong T. Barriers of access to breast reconstruction: a systematic review. Plast Reconstr Surg. 2019;143(3):465e-476e. https://doi.org/10.1097/PRS.0000000000005313
21. Huang J, Chagpar A. Factors associated with decision to undergo contralateral prophylactic mastectomy versus unilateral mastectomy. Am J Surg. 2019;218(1):170-4. https://doi.org/10.1016/j.amjsurg.2018.11.040
22. Jagsi R, Hawley ST, Griffith KA, Janz NK, Kurian AW, Ward KC, et al. Contralateral prophylactic mastectomy decisions in a population-based sample of patients with early-stage breast cancer. JAMA Surg. 2017;152(3):274-82. https://doi.org/10.1001/jamasurg.2016.4749
23. Nichols HB, Berrington de González A, Lacey JV Jr, Rosenberg PS, Anderson WF. Declining incidence of contralateral breast cancer in the United States from 1975 to 2006. J Clin Oncol. 2011;29(12):1564-9. https://doi.org/10.1200/JCO.2010.32.7395
24. Breast Cancer Association Consortium. Breast Cancer Risk Genes - Association Analysis in More than 113,000 Women. N Engl J Med. 2021;384(5):428-39. https://doi.org/10.1056/NEJMoa1913948
25. Hu C, Hart SN, Gnanaolivu R, Huang H, Lee KY, Na J, et al. A population-based study of genes previously implicated in breast cancer. N Engl J Med. 2021;384(5):440-51. https://doi.org/10.1056/NEJMoa2005936
26. Yadav S, Boddicker NJ, Na J, Polley EC, Hu C, Hart SN, et al. Contralateral breast cancer risk among carriers of germline pathogenic variants in ATM, BRCA1, BRCA2, CHEK2, and PALB2. J Clin Oncol. 2023;41(9):1703-13. https://doi.org/10.1200/JCO.22.01239
27. Morra A, Mavaddat N, Muranen TA, Ahearn TU, Allen J, Andrulis IL, et al. The impact of coding germline variants on contralateral breast cancer risk and survival. Am J Hum Genet. 2023;110(3):475-86. https://doi.org/10.1016/j.ajhg.2023.02.003
28. Li X, You R, Wang X, Liu C, Xu Z, Zhou J, et al. Effectiveness of prophylactic surgeries in BRCA1 or BRCA2 mutation carriers: a meta-analysis and systematic review. Clin Cancer Res. 2016;22(15):3971-81. https://doi.org/10.1158/1078-0432.CCR-15-1465
29. Valachis A, Nearchou AD, Lind P. Surgical management of breast cancer in BRCA-mutation carriers: a systematic review and meta-analysis. Breast Cancer Res Treat. 2014;144(3):443-55. https://doi.org/10.1007/s10549-014-2890-1
30. Buzaid AC, Achatz MI, Amorim GLS, Barrios CH, Carvalho FM, Cavalcante FP, et al. Challenges in the journey of breast cancer patients in Brazil. Desafios na jornada de pacientes com câncer de mama no Brasil. Braz J Oncol. 2020;16:e20200021. https://doi.org/10.5935/2526-8732.20200021
31. Kurian AW, Abrahamse P, Furgal A, Ward KC, Hamilton AS, Hodan R, et al. Germline genetic testing after cancer diagnosis. JAMA. 2023;330(1):43-51. https://doi.org/10.1001/jama.2023.9526
32. Simon SD, Bines J, Werutsky G, Nunes JS, Pacheco FC, Segalla JG, et al. Characteristics and prognosis of stage I-III breast cancer subtypes in Brazil: The AMAZONA retrospective cohort study. Breast. 2019;44:113-9. https://doi.org/10.1016/j.breast.2019.01.008
33. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials. Lancet Oncol. 2018;19(1):27-39. https://doi.org/10.1016/s1470-2045(17)30777-5
34. Mamtani A, Sevilimedu V, Le T, Morrow M, Barrio AV. Is local recurrence higher among patients who downstage to breast conservation after neoadjuvant chemotherapy? Cancer. 2022;128(3):471-8. https://doi.org/10.1002/cncr.33929
35. Paulinelli RR, Ribeiro LFJ, Santos TD, Caires EMS, Pontes MGM, Faria BM, et al. Oncoplastic mammoplasty with disguised geometric compensation. Surg Oncol. 2021;39:101660. https://doi.org/10.1016/j.suronc.2021.101660
36. Cavalcante FP, Silva PG de B, Lima MVA. Trends in bilateral mastectomy for cases of unilateral breast cancer in a Brazilian institute over a 10-year period. Mastology. 2021;31:1-6. https://doi.org/10.29289/2594539420210030
37. Kurian AW, Ward KC, Abrahamse P, Hamilton AS, Deapen D, Morrow M, et al. Association of germline genetic testing results with locoregional and systemic therapy in patients with breast cancer. JAMA Oncol. 2020;6(4):e196400. https://doi.org/10.1001/jamaoncol.2019.6400
Downloads
Publicado
Como Citar
Edição
Seção
Licença
Copyright (c) 2025 Francisco Pimentel Cavalcante, Tallita Moniele Gomes Pinheiro, Felipe Pereira Zerwes, Eduardo Camargo Millen, Andre Mattar, Marcelo Antonini, Fabrício Palermo Brenelli, Guilherme Garcia Novita, Antônio Luiz Frasson, Antônio Luiz Frasson, Ruffo Freitas-Junior
Este trabalho está licenciado sob uma licença Creative Commons Attribution 4.0 International License.
